Reports Q3 revenue $0.4M, consensus $80,000. “This quarter brought us important progress on multiple fronts, including the closing of a financing which extended our cash runway into the first half of 2025,” said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. “We are pleased with our progress in Synpheny-3, our ongoing pivotal study in PKU, which is also expected to readout in the first half of 2025, and we are grateful to our investigators and their staff at our clinical trial sites, as well as the PKU community for their continued support and partnership as we execute this landmark trial.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SYBX:
- Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Synlogic achieves research milestone, earns $2.5M milestone payment
- Is SYBX a Buy, Before Earnings?
- Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
- Synlogic prices 7.39M shares at $2.84 in underwritten public offering